WealthSource Partners’s Cue Biopharma CUE Stock Holding History

WealthSource Partners’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-440	Closed	-$119K	–	430
2019 Q2	$119K	Sell	440 -33	-7%	-$8.21K	0.02%	439
2019 Q1	$110K	Sell	473 -191	-29%	-$36.3K	0.02%	343
2018 Q4	$94K	Sell	664 -21	-3%	-$3.81K	0.03%	295
2018 Q3	$186K	Sell	685 -7	-1%	-$2.02K	0.05%	304
2018 Q2	$246K	Buy	+692	New	+$275K	0.07%	240

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

WealthSource Partners's CUE Position: Q3 2019 in Review

WealthSource Partners sold out of Cue Biopharma (CUE) in Q3 2019, closing a stake of 440 shares — an estimated $119K sold.

WealthSource Partners first reported a position in CUE in Q2 2018 and held it in 5 quarters. The position peaked at $246K in Q2 2018. 45 funds tracked by Wall St. Rank hold CUE as of Q3 2019.

WealthSource Partners reported no remaining Cue Biopharma position as of Q3 2019 after selling out during the quarter.
WealthSource Partners sold 440 Cue Biopharma shares in Q3 2019, an estimated $119K.
WealthSource Partners first reported a position in Cue Biopharma in Q2 2018 and held it in 5 quarters.
WealthSource Partners's Cue Biopharma position peaked at $246K in Q2 2018.
45 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2019.

Based on WealthSource Partners's 13F filing for Q3 2019, filed 15 Nov 2019.